Phase I Hepatitis C Vaccine Trial of Virosome-formulated Peptides

Pevion Biotech

Status and phase

Completed

Phase 1

Conditions

Chronic Hepatitis C

Treatments

Biological: PEV2A PEV2B

Study type

Interventional

Funder types

Industry

Identifiers

NCT00445419

PHEPC001

2006DR1345

Details and patient eligibility

About

Pevion Biotech has designed a therapeutic vaccine to treat patients who suffer from chronic hepatitis C virus infection. The vaccine is based on a combination of the PeviPRO and PeviTER platforms using synthetic peptide antigens from the hepatitis C virus. Generally, a cellular immune response by cytotoxic T-lymphocytes (CTL) seems to be crucial in overcoming a hepatitis C virus infection. In-depth research in recent years has shown that the cellular immune response is even more effective when supported by helper T-cells. Pevion Biotech's HCV vaccine candidate utilizes this effect inducing specific CTL responses (PeviTER) together with a supportive helper T cell response (PeviPRO). This virosome-based technological combination in a single product represents a new generation of modular therapeutic vaccines.

Enrollment

30 estimated patients

Sex

All

Ages

18 to 45 years old

Volunteers

Accepts Healthy Volunteers

Inclusion criteria

Healthy volunteers of both sexes
Aged between 18 and 45 years
Free of obvious health problems
With a BMI between 18.5 and 29.9 are included if they give written informed consent

Exclusion criteria